Global Cell & Gene Therapy Drug Delivery Devices Market Research Report: Forecast (2025-2030)

By Product Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle), (Size 0.5 ML, 22-Gauge Needle)), Pre-Fi...lled Syringe (Size 1.0 ML, 22-26 Gauge Needle), (Size 4.0 ML, 22-26 Gauge Needle)), Infusion Bags (Size 10 ML to 50 ML), (Size 68 ML), (Size 60 ML), (Size Up to 65 ML)), By Technology (Microchip Technology, Nano-Technology, Lipid Nanoparticles), By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis), By End-Users (Pharmaceuticals & Biotechnology Company, Academic & Research Institute, Hospitals & Clinics) Read more

Healthcare
Jul 2025
Pages 221
Report Format: PDF, Excel, PPT

Get Actionable Insights for Smarter Decisions: Regional and country reports in one place pick a location for insights and Trends.

Market Definition

Cell & gene therapies involve the extraction of protein, cells, or genetic material from the patient, modifying them, and then re-injecting into the patient to provide a highly personalized treatment. These therapies have immense potential to display long-lasting effects.

Market Insights & Analysis: Global Cell & Gene Therapy Drug Delivery Devices Market (2025-30):

The Global Cell & Gene Therapy Drug Delivery Devices Market size was valued at around USD 1.27 billion in 2024 and is projected to reach USD 2.32 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.53% during the forecast period, i.e., 2025-30.

The market is driven primarily by massive funding by numerous leading players in the technological advancements to bring cost-effective therapies & devices, coupled with the increasing number of FDA approvals for cell & gene therapies & clinical trials. Furthermore, the rising number of FDA Approvals of Cell & Gene Therapies and clinical trials to develop new medical products and provide patients with increased therapeutic choices shall also boost the market in the coming years

Report Coverage	Details
Study Period	Historical Data: 2020-23
	Base Year: 2024
	Forecast Period: 2025-30
CAGR (2023-2028)	10.53%
Regions Covered	North America: USA, Canada, Mexico
	Europe: Germany, UK, France, Italy, Spain
	Asia-Pacific: China, India, Japan, South Korea
	South America: Brazil, and Argentina
	Middle East & Africa: UAE, Saudi Arabia, Qatar, Israel, South Africa
Key Companies Profiled	Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio Inc., Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC, Helixmith Co. Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer Inc., Renova Therapeutics, Spark Therapeutics Inc., uniQure N.V., Vericel Corporation
Unit Denominations	USD Million/Billion

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

The market dynamics underwent significant disruptions in manufacturing & logistics processes and faced substantial complexities in the supply chain of materials. Owing to this, many clinical centers had to suspend their operations to combat the risk of virus exposure. Moreover, shipment delays risked the short shelf lives of cell therapies that need transportation across manufacturing sites & administration centers within tight timeframes.

However, observing the increasing spread of the dreadful disease, market players shifted their focus majorly on addressing challenges associated with the pandemic. Numerous gene therapy companies got involved in the research & manufacturing of Covid-19 vaccinations since the currently available ones are authorized for clinical development & based on mRNA or viral vector approaches. As a result, prices & reimbursements of Competitive Generic Therapy (CGTs) expanded significantly.

cell & gene therapy drug delivery devices market growth chart

Global Cell & Gene Therapy Drug Delivery Devices Market Driver:

Growing Occurrence of Chronic and Genetic Disorders – One of the leading drivers propelling the global cell and gene therapy drug delivery devices market is the increasing prevalence of chronic diseases, particularly cancer, diabetes, and genetic disorders. As these complex conditions become more widespread, there is a growing demand for advanced therapies that can offer targeted and effective treatment options. Cell and gene therapies have emerged as transformative solutions, and their success relies heavily on innovative drug delivery devices that ensure precise administration, optimal dosage, and improved patient outcomes. This surge in chronic disease cases not only fuels the adoption of these therapies but also accelerates the development and deployment of specialized delivery devices, thereby driving robust market growth.

Global Cell & Gene Therapy Drug Delivery Devices Market Opportunity:

Integration of Technological Advancements in Drug Delivery – A major opportunity in the global cell and gene therapy drug delivery devices market lies in the rapid advancement of novel drug delivery platforms and technologies. Innovations such as subdermal implants, rings, and patches are making therapy administration more precise, convenient, and patient-friendly. These advancements not only improve the bioavailability of drugs at target sites but also support the development of highly personalized treatments, opening new avenues for market expansion and better patient outcomes.

Global Cell & Gene Therapy Drug Delivery Devices Market Challenge:

Scalability and Manufacturing Complexity – One of the most significant challenges restricting the growth of the global cell and gene therapy drug delivery devices market is the issue of scalability and manufacturing complexity. As these therapies transition from clinical development to commercial-scale production, manufacturers face major obstacles in expanding processes that are often manual, labor-intensive, and highly customized for individual patients, especially in autologous therapies. The lack of automated, robust bioprocessing tools and the reliance on skilled labor drive up production costs and limit the ability to meet growing global demand. Additionally, maintaining consistent product quality while increasing batch sizes is difficult, and the need for stringent regulatory compliance further complicates scaling efforts. These factors collectively create bottlenecks in production, inflate costs, and ultimately restrict wider patient access to advanced cell and gene therapies.

Global Cell & Gene Therapy Drug Delivery Devices Market Trend:

Shift Toward Personalized and Targeted Therapies – The most significant trend shaping the market is the growing shift toward personalized and targeted therapies. As biotechnology and genetic engineering advance, there is a heightened focus on developing delivery systems that can precisely administer cell and gene therapies tailored to individual patient profiles. This trend is supported by increased investment in research and development, as well as the creation of novel delivery platforms that enhance treatment efficacy and safety.

Global Cell & Gene Therapy Drug Delivery Devices Market (2025-30): Segmentation Analysis

The Global Cell & Gene Therapy Drug Delivery Devices Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2025–2030 at the global level. Based on the analysis, the market has been further classified as:

Based on Commercialized Drugs:

Luxturna
Kymriah
Yescarta
Zolgensma
Provenge
Strimvelis

Of them all, Luxturna & Yescarta overpowered the Global Cell & Gene Therapy Drug Delivery Devices Market in 2024. Luxturna (voretigene neparvovec-rzyl) is an Adeno-Associated Virus (AAV) vector-based gene therapy. It is for the treatment of patients with confirmed biallelic RPE65 mutation-associated Inherited Retinal Dystrophy (IRD), which causes vision loss and even complete blindness in some patients.

This therapy has improved patients’ vision & their ability to move around obstructions, especially in low light, which is a crucial clinical advantage, reckoning the lack of legitimate treatments for this condition. Moreover, it shows acceptable safety levels and manageable side effects. Hence, owing to more benefits than risks associated with Luxturna, its demand is rapidly increasing worldwide.

Global Cell & Gene Therapy Drug Delivery Devices Market (2025-30): Regional Projection

Geographically, the Global Cell & Gene Therapy Drug Delivery Devices Market expands across:

North America
South America
Europe
Asia-Pacific
The Middle East and Africa

Of all the regions, North America attained majority of revenue share and is anticipated to prevail the same trend in the forecast period. It owes to the mounting number of collaborations between several small & medium enterprises and numerous conglomerates to develop cost-effective & high-quality medicines that most people can afford.

Moreover, the surging incidences of neurodegenerative problems and soaring demand to discover suitable treatments for gene disorders through research, diagnostics, & synthetic biology is another crucial aspect that contributed to the regional market growth.

In the region, the US is expected to display the fastest market growth over the forecast years. It owes to regulatory bodies like the Centre for Biologics Evaluation & Research (CBER) present in the country that focus on cell & gene therapy devices and provides scientific & regulatory advice to researchers & manufacturers for new product developments.

Global Cell & Gene Therapy Drug Delivery Devices Industry Recent Development:

2024: Pfizer collaborated with UT Southwestern Medical Center to develop improved RNA delivery technologies for genetic medicine therapies. This partnership aims to advance the understanding of genetic medicines, expand the use of artificial intelligence (AI) design methodologies, and lead to the development of new delivery technologies for potential therapies.

Gain a Competitive Edge with Our Global Cell & Gene Therapy Drug Delivery Devices Market Report

Global Cell & Gene Therapy Drug Delivery Devices Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
Global Cell & Gene Therapy Drug Delivery Devices Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.

Frequently Asked Questions

A. The Global Cell & Gene Therapy Drug Delivery Devices Market is expected to grow at a compound annual growth rate (CAGR) of 10.53% from 2025 to 2030.

A. The Global Cell & Gene Therapy Drug Delivery Devices Market size was valued at around USD 1.27 billion in 2024

A. Growing Occurrence of Chronic and Genetic Disorders is expected to drive the Global Cell and Gene Therapy Drug Delivery Devices Market during 2025-30.

A. Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio Inc., Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC, Helixmith Co. Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer Inc., Renova Therapeutics, Spark Therapeutics Inc., uniQure N.V., Vericel Corporation, and others are the top players in the global cell and gene therapy drugs delivery devices market.

A. Luxturna & Yescarta held the largest share of the global cell and gene therapy drug delivery devices market.

A. North America would present growth prospects in the Global Cell and Gene Therapy Drug Delivery Devices Market during 2025-30.

A. Shift toward personalized and targeted therapies are the key trends shaping the growth of the global cell and gene therapy drug delivery devices market.

A. Integration of technological advancements in drug delivery are the growth opportunity driving the global cell and gene therapy drug delivery devices market.

Introduction
1. Product Definition
2. Research Process
3. Assumptions
4. Market Segmentation
Executive Summary
Impact of Covid-19 on Global Cell & Gene Therapy Drug Delivery Devices Market
Global Cell & Gene Therapy Drug Delivery Devices Market Policies & Regulations
Global Cell & Gene Therapy Drug Delivery Devices Success & Growth
Global Cell & Gene Therapy Drug Delivery Devices Market Trends & Insights
Global Cell & Gene Therapy Drug Delivery Devices Market Dynamics
1. Impact Analysis
2. Drivers
3. Challenges
Global Cell & Gene Therapy Drug Delivery Devices Market Trends & Development
Global Cell & Gene Therapy Drug Delivery Devices Market Analysis, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
    1. Sub-retinal Injection Cannula
    2. Extension Tube
    3. Intravenous Catheter
    4. Sterile Insulin Syringe
      1. Size 1.0 ML, 31-Gauge Needle
      2. Size 0.5 ML, 22-Gauge Needle
    5. Pre-Filled Syringe
      1. Size 1.0 ML, 22-26 Gauge Needle
      2. Size 4.0 ML, 22-26 Gauge Needle
    6. Infusion Bags
      1. Infusion Bags (Size 10 ML to 50 ML)
      2. Infusion Bags (Size 68 ML)
      3. Infusion Bags (Size 60 ML)
      4. Infusion Bags (Size Up to 65 ML)
  2. By Technology
    1. Microchip Technology
    2. Nano-Technology
    3. Lipid Nanoparticles
  3. By Commercialized Drugs
    1. Luxturna
    2. Kymriah
    3. Yescarta
    4. Zolgensma
    5. Provenge
    6. Strimvelis
  4. By End-User
    1. Pharmaceuticals & Biotechnology Company
    2. Academic & Research Institute
    3. Hospitals & Clinics
  5. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
North America Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
  2. By Technology
  3. By Commercialized Drugs
  4. By End-User
  5. By Country
    1. US
    2. Canada
    3. Mexico
3. The US Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
4. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
5. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
South America Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
  2. By Technology
  3. By Commercialized Drugs
  4. By End-User
  5. By Country
    1. Brazil
    2. Argentina
    3. Others
3. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
4. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
  2. By Technology
  3. By Commercialized Drugs
  4. By End-User
  5. By Country
    1. The UK
    2. Spain
    3. Italy
    4. France
    5. Germany
    6. Others
3. The UK Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
4. France Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
5. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
6. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
7. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
  2. By Technology
  3. By Commercialized Drugs
  4. By End-User
  5. By Country
    1. Saudi Arabia
    2. The UAE
    3. Qatar
    4. Israel
    5. South Africa
    6. Others
Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
1. Market Size & Analysis
  1. By Revenue
  2. By Unit Sold
2. Market Share & Analysis
  1. By Product Type
  2. By Technology
  3. By Commercialized Drugs
  4. By End-User
  5. By Country
    1. India
    2. China
    3. Japan
    4. South Korea
    5. Others
3. China Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
4. India Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
5. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
6. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook, 2018-2028
  1. Market Size & Analysis
    1. By Revenue
    2. By Unit Sold
  2. Market Share & Analysis
    1. By Product Type
    2. By Technology
Competitive Benchmarking
1. Competition Matrix
  1. Company Overview
  2. Product/Business Segment Overview
  3. Regulatory & Legal Development
  4. Company Strategies
  5. SWOT Analysis
Company Profile
1. Amgen Inc.
2. Bausch & Lomb Incorporated
3. Becton, Dickinson and Company
4. Bluebird bio Inc.
5. Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
6. Dendreon Pharmaceuticals LLC
7. Helixmith Co. Ltd (ViroMed Co., Ltd)
8. Human Stem Cells Institute
9. Kite Pharma Inc.
10. Kolon TissueGene, Inc.
11. Novartis AG
12. Orchard Therapeutics plc.
13. Pfizer Inc.
14. Renova Therapeutics
15. Spark Therapeutics Inc.
16. uniQure N.V.
17. Vericel Corporation
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Inquire Before Buying

Talk to our Consultant

Request Customization

Global / Regional Reports

Report Walkthrough

Related Reports

Customization Offered